MEISHIANG JANG, PhD

*** * **** **. ***** Prospect, IL 60056

Phone: 847-***-****

acgmrh@r.postjobfree.com

CAREER PROFILE

Accomplished research associate with twelve years? laboratory experience in drug discovery development in

pharmaceutical environments and eight years? cancer research experience in academic area plus pharmacy

education and clinical research training background. Expertise in generating scientific reports/proposals and

developing assays/protocols to deliver relevant data. Experience in immunoassay, enzymatic and cell-based

techniques development and validation of assays for accuracy and reproducibility. Extensive knowledge and

skills in cancer cell biology, signal transduction, apoptosis, micro RNA, molecular biology, immunology and

oncology. Open and clear communicator at all levels with demonstrated business and strategic vision and

disciplined execution.

SKILLS

?

? ?

In vitro bioassays, signal Immunoassays, apoptosis

transduction assays

? ?

Enzymatic techniques; cell Cellular assay development

?

culture FACS / ELISA / PAGE /

? Quality assurance/data PCR

?

accountability Method

? Document archiving/result development/validation

publication ?

ATTRIBUTES

? Maximized operational efficiency of project teams by conducting and analyzing

results of research. Implemented new assigned projects with high efficiency and performance

to achieve project goals.

? As a project leader to present promising proposals to convince R&D decision-

making team at company headquarters in Japan to stage-up the project to next drug

development step.

? As a lead author, published personal first paper in Science, with the novel

discovery of a natural product from grape with potential efficacy to prevent cancer.

EXPERIENCE

ASTELLAS RESEARCH INSTITUTE OF AMERICA, LLC Skokie, IL 2005 - 2013

Manager, Transplantation and Immunology 2011 to Present

Reported to Assistant Director, Transplantation and Immunology. Responsible for planning, performing,

monitoring, recording, reporting, and archiving laboratory studies to analyze clinical samples. Provided

reliable experimental data and scientific support in drug discovery and pre-clinical development stages.

? Utilizing the skills in cell and molecular biology to investigate the molecular mechanism and

signal transduction to explore the potential novel targets for autoimmune diseases.

? Prepared project proposals for further development of potential therapeutic compounds in drug

discovery research. Managed 5-6 study protocols simultaneously.

? Proficient work competence in molecular bioassays (electrophoresis, PAGE, PCR, FACS), cell

culture assay techniques (cell plating, staining, and subculture).

Principal Scientist, Transplantation and Immunology 2005 ? 2011

Followed GLP principles to perform laboratory studies and generate reliable and reproducible scientific data

to achieve project goals. Conducted research and analyzed data with SOP compliance to identify potential

biomarkers and provide input for selection of candidates for non-clinical studies development. Responsible

for data quality, accountability and timely data collection, documentation and reporting.

? Generated development plans, experimental protocol designs and strategies for potential

compounds. Performed instrumentation validation and tracked reagent/material certification.

Conducted extensive experiments of immunoassays and molecular bioassays.

MEISHIANG JANG, PhD Page Two

FUJISAWA RESEARCH INSTITUTE OF AMERICA Evanston, IL 2001 ? 2005

Senior Scientist, Transplantation and Immunology 2002 ? 2005

? Provided instruction and management to project team members.

? Developed effective working relationships with both colleagues and external contacts.

? Identified and evaluated potential therapeutic targets for drug development by using extensive

laboratory techniques including ELISA, SDS-PAGE, Western Blot, PCR, RT-PCR, FACS, cell culture,

HPLC, GC, MS, UV etc.

? As a key team member, ensured quality, data integrity and timeliness.

Scientist, Transplantation and Immunology 2001 ? 2002

EDUCATION and TRAINING

2013 Advanced Post-Graduate Training Program in Clinical Research &

Pharmacovigilance

James Lind Institute, Montreal, Canada

1998 ? 2001 Post Doctoral Fellow in cancer immunology

Medical Center, Loyola University, Maywood, IL, USA

Main research: Notch signaling in multimodality cancer therapy and

regulation of apoptosis and cell cycle pathways.

1998 PhD Pharmacognosy

University of Illinois at Chicago, Chicago, IL, USA

Thesis accomplishment: The first group to identify resveratrol

as a new cancer preventive agent from grape and published research work

in Science.

1990 BS Pharmacy

National Taiwan University, Taipei, Taiwan, ROC

PATENT

J.M. Pezzuto, R.C. Moon and M. Jang. Cancer chemopreventative composition and method. 1999

US Patent Number 6,008,260.

AFFILIATIONS

? Healthcare Businesswomen?s Association (HBA), Chicago Chapter, Program volunteer

? ChemPharma Professional Association

? Association of Clinical Research Professionals

MEISHIANG JANG, PhD ADDENDUM

PUBLICATIONS

1. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR,

Kinghorn AD, Mehta RG, Moon RC, and Pezzuto JM. Cancer chemopreventive activity of

resveratrol, a natural product derived from grapes. Science, 275: 218-220, 1997.

2. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Inoue H, Jang M, Pezzuto JM, and

Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-

treated human mammary epithelial cells. J. Biol. Chem., 273: 218**-*****, 1998.

3. Jang M, and Pezzuto JM. Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced

oxidative events and gene expression in mouse skin. Cancer Lett., 134: 81-89, 1998.

4. Jang M, and Pezzuto JM. Resveratrol blocks eicosanoid production and chemically-induced cellular

transformation: Implications for cancer chemoprevention. Pharm. Biol., 36: 28-34, 1998.

5. Jang M, and Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp. Clin. Res., 25

65-77, 1999.

6. Jang M, Zlobin A, Kast WM, and Miele L. Notch signaling as a target in multimodality cancer

therapy. Curr. Opin. Mol. Ther., 2: 55-65, 2000.

7. Zlobin A, Jang M, and Miele L. Toward the rational design off cell fate modifiers: notch signaling as a

target for novel biopharmaceuticals. Curr. Pharm. Biotechnol., 1: 83-106, 2000.

8. Pan F, Ebbs A, Wynn C, Erickson L, Jang M, Crews G, Fisniku O, Kobayashi M, Paul LC,

Benediktsson H, and Jiang AH. FK778, a powerful new immunosuppressant, effectively reduces

functional and histologic changes of chronic rejection in rat renal allografts. Transplantation. 75:

1110-1114, 2003.

9. Jang M, Miao H, Carlesso N, Shelly L, Zlobin A, Darack N, Qin JZ, Nickoloff BJ, and Miele L. Notch-

1 regulates cell death independently of differentiation in murine erythroleukemia cells through

multiple apoptosis and cell cycle pathways. J. Cell Physiol. 199: 418-433, 2004.

10. Erickson L, Crews G, Pan F, Fisniku O, Jang M, Wynn C, Kobayashi M, Jiang H. Unique gene

expression profiles of heart allograft rejection in the interferon regulatory factor-1-deficient

mouse. Transpl Immunol. 13(3):169-175, 2004.

11. Pan F, Fisniku O, Wynn C, Erickson LM, Crews G, Jang M, Sudo Y, Tamura K, Kobayashi M,

Benediktsson H, and Jiang H. PG490-88, a new immunosuppressant, effectively prevents

acute and chronic rejection in rat renal allografts. Transplant Proc. 37(1):134-136, 2005

12. Fisniku O, Pan F, Wynn C, Erickson LM, Crews G, Jang M, Sudo Y, Tamura K, Kobayashi M,

Benediktsson H, Jiang H. Protective effects of PG490-88 on chronic allograft rejection by

changing intragraft gene expression profiles. Transplant Proc. 37(4):1962-1964, 2005

13. Jiang H, Pan F, Erickson L, Jang M, Sanui T, Kunisaki Y, Sasazuki T, Kobayashi M, and Fukui Y.

Deletion of DOCK2, a regulator of the actin cytoskeleton in lymphocytes, suppresses cardiac

allograft rejection. J. Exp. Med., 202: 1121-1130, 2005.

14. Jang M, Pan F, Erickson L, Fisniku O, Crews G, Wynn C, Hong IC, Tamura K, Kobayashi M, and

Jiang H. A blocking anti-CD28-specific antibody induces long-term heart allograft survival by

suppression of the PKC theta-JNK signal pathway. Transplantation, 85: 1051-1055, 2008.

Contact this candidate